Mangoceuticals clarifies GLP-1 weight-management program launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall St ends higher on chip stocks recovery; earnings in focus
- Oil prices rise to five-week high on US-Iran attacks, Houthi blockade threat
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
- Myriad Genetics launches four-in-one prenatal genetic screen
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
November 13, 2025 7:37 PM ESTDallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (Mangoceuticals or the Company) is issuing the following clarification regarding its press release issued earlier this morning titled Mangoceuticals Partners with Eli Lilly and Novo Nordisk.
The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time,... More
